Zinger Key Points
- MK-1084 + cetuximab + mFOLFOX6 showed up to 66% unconfirmed ORR in KRAS G12C-mutated CRC patients.
- Zilovertamab vedotin at 1.75 mg/kg plus R-GemOx showed a 56.3% ORR in relapsed/refractory DLBCL patients.
- 3 Summer "Power Patterns" Are About to Trigger (One With 90% Win Rate) - Get The Details Now
Merck & Co Inc MRK on Friday shared safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study of MK-1084 alone and in combination with other therapies.
The study included patients with KRAS G12C-mutant solid tumors, advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
In patients with advanced KRAS G12C-mutated CRC and NSCLC, MK-1084, either as monotherapy or in combinations, demonstrated a manageable safety profile and antitumor activity.
Also Read: Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
In CRC, the study assessed MK-1084 as monotherapy, as well as in combination with cetuximab with or without chemotherapy (oxaliplatin and leucovorin plus 5-fluorouracil [mFOLFOX6]). The study evaluated the overall response rate (ORR) in previously treated patients:
- MK-1084 monotherapy (N=53)- Confirmed ORR of 38% and unconfirmed ORR of 43%.
- MK-1084 + cetuximab (N=39)-Confirmed ORR of 46% and unconfirmed ORR of 56%.
- MK-1084 + cetuximab + mFOLFOX6 (N=29)-Confirmed ORR of 38% and unconfirmed ORR of 66%.
In addition to KANDLELIT-001, MK-1084 will be investigated in:
- Phase 3 KANDLELIT-012 study, which is investigating MK-1084 in combination with cetuximab and mFOLFOX6 for the first-line treatment of certain patients with locally advanced unresectable or metastatic CRC who have KRAS G12C-mutated tumors.
- Phase 3 KANDLELIT-004 study, which is investigating MK-1084 in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic NSCLC who have KRAS G12C-mutated tumors and express PD-L1 (TPS ≥50%).
Concurrently, Merck announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study of zilovertamab vedotin in combination with standard-of-care rituximab and gemcitabine-oxaliplatin (R-GemOx) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with eight complete responses (CR) and one partial response (PR).
At a median follow-up of 18.1 months in patients receiving the 1.5 mg/kg dose of zilovertamab vedotin (n=15), ORR was 26.7% (3 CR [20.0%], 1 PR [6.7%]) and median DOR was 14.4 months.
At a median follow-up of 9.3 months for patients receiving the 2.0 mg/kg dose (n=7), the ORR was 57.1% (3 CR [42.9%], 1 PR [14.3%]) and median DOR was not reached.
Seven dose-limiting toxicities occurred across all participants.
Based on these results and accompanying safety data, the recommended Phase 2 dose of zilovertamab vedotin was determined to be 1.75 mg/kg when used with R-GemOx.
Price Action: MRK stock is up 1.09% at $77.24 at the last check on Friday.
Read Next:
Image: Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.